Peel Therapeutics, a Salt Lake City, UT-based clinical-stage biotech company, secured $9M in funding, bringing its total seed financing to $36M.
The company intends to use the funds to advance clinical and pre-clinical programs.
Led by Joshua Schiffman, M.D., CEO and Co-founder, Peel Therapeutics is a clinical-stage biotech company that is advancing a therapeutic pipeline to treat a spectrum of devastating conditions, with a near-term focus on cancer and inflammation.
The company has raised a total of $36M in seed financing, plus over $3M in non-dilutive capital including National Institutes of Health Small Business Innovation Research and Small Business Technology Transfer funding.
Peel also expanded its Board of Directors to support and guide the company through this rapid growth stage. The new additions include Ryan Watts, CEO, Denali Therapeutics and Carin Canale-Theakston, CEO, Evoke Canale.
FinSMEs
23/02/2023